Foster City, California-based Gilead Sciences, Inc. (GILD) is a biopharmaceutical company. It discovers, develops, and commercializes medicines in the areas of unmet medical need. With a market cap of $139.9 billion, Gilead’s operations span the United States, Europe, and internationally.

Companies worth $10 billion or more are generally described as “large-cap stocks.” GILD fits this bill perfectly. Given the company’s extensive operations and dominance in the healthcare sector, its valuation above this mark is unsurprising.

Gilead touched its 10-year high of $121.83 on Aug. 12 and is currently trading 7.3% below this peak. Meanwhile, GILD stock has inched up 3.4% over the past three months, notably underperforming the Nasdaq Composite’s ($NASX) 10.8% surge during the same time frame.

However, over the longer term, the pharma giant’s performance has remained much more impressive. GILD stock prices have gone up 22.3% on a YTD basis and 41.8% over the past 52 weeks, notably outperforming NASX’s 11.3% gains in 2025 and 25.5% surge over the past year.

To confirm the bullish trend, GILD stock has remained consistently above its 200-day moving average over the past year and above its 50-day moving average since late May.

Gilead Sciences’ stock prices surged 8.3% in the trading session following the release of its better-than-expected Q2 results on Aug. 7. The company’s topline for the quarter inched up 1.8% year-over-year to $7.1 billion, driven by higher HIV, Livdelzi (seladelpar), and Trodelvy (sacituzumab govitecan-hziy) sales, partially offset by lower chronic hepatitis C virus (“HCV”) and Veklury (remdesivir) sales. This figure surpassed the Street’s expectations by almost 2%. Meanwhile, its adjusted EPS remained steady at $2.01 and surpassed the consensus estimates by 3.1%.

Moreover, GILD has significantly outperformed its peer, Bristol-Myers Squibb’s (BMY) 16% plunge in 2025 and 6% decline over the past 52 weeks.

Among the 29 analysts covering the GILD stock, the overall consensus rating is a “Strong Buy.” Its mean price target of $126.33 suggests an 11.8% upside potential from current price levels.